“For almost 40 years, the groundbreaking law known as the Hatch-Waxman Act (HWA) has been highly successful in spurring the development of life-saving new treatments while at the same time vastly broadening the availability of low-cost generic pharmaceuticals."
Digital Resources | December 13, 2018 | Employee Retention, Key Resources for Individual Growth
An analysis by The Boston Consulting Group showing that the best-performing companies show no gender gap and provides steps leadership can take to improve.
Diversity & Inclusion Toolkit | December 12, 2018 | Employee Retention, HR Policies & Practices for a Flexible Workplace
Washington, DC (October 26, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Volume III Type 2 Diabetes and Obesity Therapeutics, the third in a series on the current funding and R&D…
Washington, D.C. (November 30, 2018) – Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the United States-Mexico-Canada Agreement (USMCA):“The signing of today’s trade agreement has effectively prioritized biotechnology…
Brent Erickson, Executive Vice President of the Biotechnology Innovation Organization’s (BIO) Industrial and Environmental Section, released the following statement today on final Renewable Fuel Standard (RFS) volumes for 2019 and the Biomass-Based Diesel Volumes for 2020 published by the…